Markets:

Overview

News

Currencies

International

Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.460 -0.020 (-1.35%)

Streaming Delayed Price Updated: 3:45 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Gold Gains 1%; Richmond Fed Manufacturing Index Falls In December ↗

December 27, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 80 points on Wednesday. The Dow traded up 0.22% to 37,626.76 while the NASDAQ rose 0.06% to 15,084.02. The S&P...

Via Benzinga

Topics Economy Stocks

Why Coherus BioSciences Stock Is Climbing Today ↗

December 27, 2023

Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Wednesday after the company announced the FDA approval of its pegfilgrastim delivery device, Udenyca Onbody.

Via Benzinga

US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY ↗

December 27, 2023

U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining more than 20 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.08% to 37,575.13 while...

Via Benzinga

Topics Stocks

Why Ascent Industries Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗

December 27, 2023

Shares of Ascent Industries Co. (NASDAQ: ACNT) rose sharply in pre-market trading as the company reported the sale of the business of Specialty Pipe & Tube for around $55 million in an all-cash deal....

Via Benzinga

What 6 Analyst Ratings Have To Say About Coherus BioSciences ↗

November 28, 2023

Via Benzinga

Analyst Ratings for Coherus BioSciences ↗

November 08, 2023

Via Benzinga

Why Coherus Biosciences Stock Dropped Today ↗

November 07, 2023

Coherus missed estimates for the third quarter and lowered its full-year outlook.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 27, 2023

Via Benzinga

S&P 500, Nasdaq Set For Wobbly Open As Santa Claus Rally Fades: Analyst Sees Final Trading Sessions As 'Last Great Buying Opportunity' ↗

December 27, 2023

U.S. stocks may face challenges in maintaining their upward momentum on Wednesday, as index futures suggest a flat start. In the absence of significant catalysts, the market might experience a lack of...

Via Benzinga

Topics Stocks

Coherus BioSciences And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

December 27, 2023

U.S. stock futures were slightly lower this morning, with the Dow Jones futures falling around 5 points on Wednesday.

Via Benzinga

Topics Stocks

Coherus BioSciences, Ascent Industries And 3 Stocks To Watch Heading Into Wednesday ↗

December 27, 2023

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 26, 2023

Via Benzinga

Coherus BioSciences Stock Is Soaring After-Hours - Here's Why ↗

December 26, 2023

Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher in Tuesday's after-hours session following the company's announcement of the U.S.

Via Benzinga

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

December 26, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street ↗

December 24, 2023

These two biotech stocks could be poised for a trend reversal.

Via The Motley Fool

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

December 11, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences Announces CFO Transition Plans

December 07, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

December 06, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments ↗

December 02, 2023

LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...

Via Talk Markets

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical

November 28, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Why Coherus BioSciences Was Plummeting This Week ↗

November 10, 2023

The company has been punished harshly for a worse-than-expected quarter.

Via The Motley Fool

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 07, 2023

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 07, 2023

Via Benzinga

Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗

November 07, 2023

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 07, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 07, 2023

It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.

Via InvestorPlace

Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 07, 2023

U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 06, 2023

Via Benzinga

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

November 06, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

All News about Coherus Oncology, Inc. - Common Stock

Starting at /week.